Compare Vanguard Mega Cap Growth ETF (MGK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Neurocrine Biosciences Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $94.9 (market cap $33.70B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MGK | NBIX | |
|---|---|---|
Market Cap | $33.70B | $14.36B |
Volume | 1,362,010 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $185.50 |
52-Week Low | $70.70 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK trades at $94.92, down 0.2% on the day, with a bullish technical signal from moving averages but bearish momentum from oscillators. The ETF focuses on large-cap US growth stocks with heavy technology concentration, offering low 0.05% expense ratio exposure to companies like Nvidia, Apple, and Microsoft. Recent articles highlight its strong five-year performance and appeal for long-term growth investors seeking mega-cap stability.
MGK presents a compelling growth ETF option with concentrated mega-cap exposure, though its tech-heavy composition increases sector-specific risk. The fund's low costs and historical outperformance make it suitable for investors with higher risk tolerance, while current technical indicators suggest potential near-term consolidation after recent gains.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
